Why the study?
Does dipyridamole prevent thromboembolic disease?
Does dipyridamole prevent thromboembolic disease?
Answers are grounded in this paper and cite their sources.
The article questions the clinical efficacy of dipyridamole as an antithrombotic drug despite its widespread use and significant cost to the NHS.
Dipyridamole (Persantin-Boehringer Ingelheim) was introduced in 1959 as a vasodilator for the treatment of angina, but it is now little used for this purpose. The discovery of its effects on platelets has led to its widespread use in a variety of thrombotic conditions, both alone and in combination with other drugs. The manufacturer claims that dipyridamole “offers a real opportunity in the prevention of thromboembolic disease” and the NHS spends well over £5 million a year on the drug. What is the evidence for its clinical efficacy?
No takes yet. Share an insight, caveat, or question.
A 1984 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: